Logotipo do repositório

Exploring the latest breakthroughs in rhodesain inhibitors for African trypanosomiasis

dc.contributor.authorChiba, Diego Eidy [UNESP]
dc.contributor.authordos Santos Fernandes, Guilherme Felipe
dc.contributor.authordos Santos, Jean Leandro [UNESP]
dc.contributor.authorScarim, Cauê Benito [UNESP]
dc.date.accessioned2026-05-07T14:50:29Z
dc.date.issued2024-02-02
dc.description.abstractHuman African Trypanosomiasis is a serious public health concern, and new chemical therapeutic agents need to be developed to combat this disease. Rhodesain (RhD) inhibitors have shown promising results in medicinal chemistry, specifically against Trypanosoma brucei. These inhibitors target the cysteine protease RhD, which is essential for the survival of T. brucei. However, as the pharmaceutical industry lacks interest in these inhibitors, the development of drugs based on them is challenging. In this review, we showed the impact of RhD inhibitors on medicinal chemistry in the past 10 years (2013–2022), particularly against T. brucei, showing interesting RhD-based inhibitors, including peptidomimetic inhibitors such as Michael acceptors, cyanide groups, 3-bromoisoxazole, benzodiazepine, among others, as well as non-peptidyl inhibitors. Peptidomimetic inhibitors (5–7, 9–15, and 17) exhibited the highest potency with respect to dissociation constant (Ki) values for rhodesain, demonstrating promising activity against T. brucei targeting rhodesain. Thus, we explored recent advancements and perspectives in the context of RhD for potential treatments in sleeping sickness, highlighting its relevance in drug discovery applications.
dc.description.affiliationSchool of Pharmaceutical Science, State University of São Paulo (Unesp), 14800-903, Araraquara, Brazil
dc.description.affiliationUniversity College London (UCL), 20 Gordon Street, WC1H 0AJ, London, UK
dc.description.affiliationUnespSchool of Pharmaceutical Science, State University of São Paulo (Unesp), 14800-903, Araraquara, Brazil
dc.identifierhttps://app.dimensions.ai/details/publication/pub.1168538819
dc.identifier.dimensionspub.1168538819
dc.identifier.doi10.1007/s00044-024-03189-0
dc.identifier.issn1054-2523
dc.identifier.issn1554-8120
dc.identifier.orcid0000-0003-2844-6402
dc.identifier.orcid0000-0002-2460-2829
dc.identifier.orcid0000-0002-2540-6395
dc.identifier.urihttps://hdl.handle.net/11449/323445
dc.publisherSpringer Nature
dc.relation.ispartofMedicinal Chemistry Research; n. 3; v. 33; p. 354-369
dc.rights.accessRightsAcesso restritopt
dc.rights.sourceRightsclosed
dc.sourceDimensions
dc.titleExploring the latest breakthroughs in rhodesain inhibitors for African trypanosomiasis
dc.typeArtigopt
dspace.entity.typePublication
relation.isOrgUnitOfPublication95697b0b-8977-4af6-88d5-c29c80b5ee92
relation.isOrgUnitOfPublication.latestForDiscovery95697b0b-8977-4af6-88d5-c29c80b5ee92
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt

Arquivos